Literature DB >> 35059924

Novel long non-coding RNA lncAMPC downregulates PTEN via miR-214 to promote nasopharyngeal carcinoma progression.

Xianqing Li1, Shunlin Ouyang2.   

Abstract

Long non-coding RNAs (lncRNAs) are a type of non-coding RNAs with transcript lengths exceeding 200 nt. lncRNAs suppress or promote cancer mainly by regulating gene expression. The aim of this study was to explore the role of lncRNAs activated in metastatic PCa (lncAMPC) in nasopharyngeal carcinoma (NPC). Total RNAs were isolated from NPC and adjacent non-tumor tissues from 60 NPC patients and subjected to RT-qPCR to analyze differential expression of lncAMPC and miR-214. The roles of lncAMPC and miR-214 in regulating PTEN expression were analyzed using RT-qPCR and Western blot. Cell proliferation was analyzed using the BrdU assay. The results showed that lncAMPC was overexpressed in NPC tissues and was localized in both nuclei and cytoplasms of NPC cells. MiR-214 was positively correlated with lncAMPC. LncAMPC overexpression upregulated miR-214 and indirectly downregulated PTEN via miR-214. BrdU incorporation assay showed that lncAMPC and miR-214 overexpression increased cell proliferation. PTEN overexpression completely reversed the promoting effects of lncAMPC and miR-214 overexpression on cell proliferation. Therefore, lncAMPC might downregulate PTEN via miR-214 to increase NPC cell proliferation.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cell cycle; LncAMPC; Nasopharyngeal carcinoma; PTEN; miR-214

Mesh:

Substances:

Year:  2022        PMID: 35059924     DOI: 10.1007/s11010-021-04323-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  21 in total

Review 1.  Management of locally recurrent nasopharyngeal carcinoma.

Authors:  Anne W M Lee; Wai Tong Ng; Jimmy Y W Chan; June Corry; Antti Mäkitie; William M Mendenhall; Alessandra Rinaldo; Juan P Rodrigo; Nabil F Saba; Primož Strojan; Carlos Suárez; Jan B Vermorken; Sue S Yom; Alfio Ferlito
Journal:  Cancer Treat Rev       Date:  2019-08-21       Impact factor: 12.111

Review 2.  Anti-EGFR therapies in nasopharyngeal carcinoma.

Authors:  Xishan Chen; Renba Liang; Xiaodong Zhu
Journal:  Biomed Pharmacother       Date:  2020-08-21       Impact factor: 6.529

Review 3.  Nasopharyngeal carcinoma.

Authors:  Melvin L K Chua; Joseph T S Wee; Edwin P Hui; Anthony T C Chan
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321

Review 4.  Advances in systemic treatment for nasopharyngeal carcinoma.

Authors:  Wan-Ling Tan; Eng-Huat Tan; Darren Wan-Teck Lim; Quan-Sing Ng; Daniel Shao-Weng Tan; Amit Jain; Mei-Kim Ang
Journal:  Chin Clin Oncol       Date:  2016-04

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

6.  Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers.

Authors:  Warut Tulalamba; Tavan Janvilisri
Journal:  Int J Cell Biol       Date:  2012-03-05

Review 7.  Molecular Targeted Therapy in the Management of Recurrent and Metastatic Nasopharyngeal Carcinoma: A Comprehensive Literature Review.

Authors:  Abdulaziz A Almobarak; Alaeddin B Jebreel; Ahmed Abu-Zaid
Journal:  Cureus       Date:  2019-03-09

8.  Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma.

Authors:  Shanthi Sabarimurugan; Chellan Kumarasamy; Siddhartha Baxi; Arikketh Devi; Rama Jayaraj
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

9.  Nasopharyngeal carcinoma: A review of current updates.

Authors:  Lei Wu; Churong Li; Li Pan
Journal:  Exp Ther Med       Date:  2018-02-20       Impact factor: 2.447

10.  Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.

Authors:  Fangfang Kong; Junjun Zhou; Chengrun Du; Xiayun He; Lin Kong; Chaosu Hu; Hongmei Ying
Journal:  BMC Cancer       Date:  2018-11-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.